Feed aggregator

Key nose cells identified as likely COVID-19 virus entry points

World Pharma News - Thu, 04/23/2020 - 12:00
Two specific cell types in the nose have been identified as likely initial infection points for COVID-19 coronavirus. Scientists discovered that goblet and ciliated cells in the nose have high levels of the entry proteins that the COVID-19 virus uses to get into our cells. The identification of these cells by researchers from the

AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients

World Pharma News - Thu, 04/23/2020 - 10:00
AstraZeneca and Saint Luke's Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious complications, such as organ failure.

AGT CEO Jeff Galvin on the Future of the Gene and Cell Therapy Industry

Biospace news - Thu, 04/23/2020 - 02:00
Jeff Galvin, CEO of American Gene Technologies (AGT), had 30 years of business and entrepreneurial experience in Silicon Valley during the formative years of the personal computing and internet era.

Leaked Study Data Suggests Gilead's Remdesivir Did Not Benefit COVID-19 Patients

Biospace news - Thu, 04/23/2020 - 02:00
Shares of Gilead Sciences fell after reports suggest remdesivir failed to distinguish itself as a treatment for COVID-19 in a clinical study conducted in China. But, there are some questions about the veracity of the study.

Affinivax Closes $120 Million Financing Round to Support Vaccine Development Program

Biospace news - Thu, 04/23/2020 - 02:00
Cambridge, Mass.-based Affinivax completed a $120 million Series B financing round that will be used to advance its vaccine and immunotherapy candidates.

Biopharma Update on the Novel Coronavirus: April 23

Biospace news - Thu, 04/23/2020 - 02:00
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 23, 2020.

BioSpace Global Roundup, April 23

Biospace news - Thu, 04/23/2020 - 02:00
Biopharma and life sciences groups from across the globe provide updates on their business and pipelines.

Sanofi Hits the Mark in Phase II MS Trial with Experimental BTK Inhibitor

Biospace news - Thu, 04/23/2020 - 02:00
The company said the treatment significantly reduced disease activity as measured by magnetic resonance imaging.

GlobalData Report: Top 20 Pharma Companies Lost $2.6 Trillion Market Cap in Q1

Biospace news - Thu, 04/23/2020 - 02:00
The COVID-19 pandemic is having a devastating effect on global business and biopharma companies are not excluded.

Vaccine Expert Claims He Was Ousted for Opposing White House's Promotion of Unproven COVID-19 Drugs

Biospace news - Thu, 04/23/2020 - 02:00
In a statement to the New York Times, Bright said he has pushed for science, not politics, as the key to battling the pandemic.

Pluristem Advances Placental Cells to Modulate COVID-19 Cytokine Storm

Biospace news - Thu, 04/23/2020 - 02:00
Plurisitem Therapeutics’ PLX (Placental eXpanded) cells are showing promise as a therapy for patients with severe cases of COVID-19.

Study Shows Coronavirus Could Be Attacking Certain Cells in the Body

Biospace news - Thu, 04/23/2020 - 02:00
"Our goal is to get information out to the community and to share data as soon as is humanly possible, so that we can help accelerate ongoing efforts in the scientific and medical communities," said Alex K. Shalek, the Pfizer-Laubach Career Development Associate Professor of Chemistry.

Oligonucleotide Therapeutics and Delivery Conference 2020

World Pharma News - Wed, 04/22/2020 - 12:00
16 - 17 September 2020, London, UK.
Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules.

'Own' immune cells to target infectious diseases including COVID-19

World Pharma News - Wed, 04/22/2020 - 10:00
The engineering of specific virus-targeting receptors onto a patient's own immune cells is now being explored by scientists from Duke-NUS Medical School (Duke-NUS), as a potential therapy for controlling infectious diseases, including the COVID-19-causing virus, SARS-CoV-2.

Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments

World Pharma News - Tue, 04/21/2020 - 12:00
Bayer announced today its Canadian organization Bayer Inc., Mississauga, Ontario, will partner with the Population Health Research Institute (PHRI) in launching a major clinical research program aimed at identifying potential treatments against COVID-19. The two studies will evaluate the safety and efficacy of different combination therapies including Bayer's chloroquine and interferon beta-1b.

Oxford COVID-19 vaccine programme opens for clinical trial recruitment

World Pharma News - Tue, 04/21/2020 - 10:00
University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won’t be ready for some weeks still.

Lopinavir/ritonavir and Arbidol not effective for mild-to-moderate COVID-19 in adults

World Pharma News - Mon, 04/20/2020 - 12:00
An exploratory randomized, controlled study on the safety and efficacy of either lopinavir/ritonavir (LPV/r) or Arbidol - antivirals that are used in some countries against HIV-1 and to treat influenza, respectively - as treatments for COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, suggests that neither drug improves the clinical outcome of patients hospitalized with mild-to-moderate cases of the disease over supportive care.

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

World Pharma News - Mon, 04/20/2020 - 10:00
Sanofi and GSK have signed a letter of intent to enter into a collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.

Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to

Seattle Genetics' Tukysa Earns FDA Approval for HER2+ Breast Cancer

Biospace news - Mon, 04/20/2020 - 02:00
The drug came out of Project Orbis, a multinational partnership between the FDA, the Australian Therapeutic Goods Administration, Health Canada, Health Sciences Authority and Swissmedic.

Novartis Launches Phase III Study of Hydroxychloroquine in COVID-19 Patients

Biospace news - Mon, 04/20/2020 - 02:00
The trial will be conducted at more than a dozen sites across the United States.